European Journal of Cancer Volume 32A, 1996 List of Contents and Author Index © PERGAMON Supplement to European Journal of Cancer European Journal of Cancer FOUNDING EDITOR: Henri Tagnon, Brussels, Belgium PAST EDITOR: Michael Peckham, London, UK EDITOR-IN-CHIEF: Hans-Jérg Senn, Interdisciplinary Oncology Centre, Department of Medicine C, Kantonsspital CH-9007, St Gallen, Switzerland EDITOR EXPERIMENTAL Ian Hart, Richard Dimbleby Department of Cancer Research, St Thomas’ Hospital, Lambeth ONCOLOGY: Palace Road, London SE] 7EH, UK ASSOCIATE EDITORS: - Radiotherapy Michel Bolla, Grenoble, France - Epidemiology Jan Willem Coebergh, Eindhoven, The Netherlands - Cancer in the Elderly Silvio Monfardini, Napoli, Italy - North America Larry Norton, New York, USA - Paediatric Oncology Jon Pritchard, London, UK - Surgical Oncology Peter M. Schlag, Berlin, Germany EDITORIAL OFFICE: European Journal of Cancer, Royal College of Surgeons, 35-43 Lincoln’s Inn Fields, London WC2A 3PN, UK. Tel: (+44) 171 430 0100; Fax: (+44) 171 430 0072 — London Delphine Purves, Scientific Editor Brad Timms, Editorial Assistant — St Gallen Manfred Lehnert, Assistant Editor (Translational Research) Beat Thiirlimann, Assistant Editor (Clinical Oncology) Armanda Schiess, Editorial Secretary EDITORIAL CONSULTANTS M. Aapro Italy J.L. Habrand France H.T. Mouridsen Denmark P. Alberto Switzerland C.H. Heldin Sweden M. Namer France K. Antman USA C. Henderson USA D.R. Newell UK J.P. Armand France G. Henze Germany G. Peters The Netherlands H. Bartelink The Netherlands R. Herrmann Switzerland W.P. Peters USA M. Baum UK B. Hirt Switzerland K. Pritchard-Jones UK W. Birchmeier Germany J.C. Horiot France D. Raghavan USA W. Bodmer UK C.H. Huber Germany G. Ries Switzerland G. Bonadonna Italy H. Huber Austria C.M. Rudenstam Sweden P. Boyle Italy D.C. Ihde USA S.E. Salmon USA G. Canellos USA R. Jakesz Austria R. Sauer Germany A. Carbone Italy V.C. Jordon USA J.H. Scarffe UK M. Castiglione Switzerland W.F. Jungi Switzerland H.J. Schmoll Germany J. Collard The Netherlands M. Kasler Hungary R. Souhami UK A. Costa Italy S.B. Kaye UK P. Steeg USA J. Cuzick UK L. Kelland UK C.A. Stiller UK Y. De Clerck USA J. Klastersky Belgium I. Tannock Canada M. D’Incalci Jtaly P. Kleihues France J.P. Thierry France D.-I. W. Dichting Germany F. Levi Switzerland N. Trapeznikov Russia J. Estape Spain M.E. Lippman USA E. van der Schueren Belgium I. Fentiman UK H. Ludwig Austria J. van Dongen The Netherlands B. Fisher USA P. Maguire UK C. van Kalken The Netherlands G. Gahrton Sweden J.G. McVie UK A.T. van Oosterom Belgium G. Gasparini /taly . Mertelsmann Germany U. Veronesi /taly R. Giavazzi Italy . Meunier Belgium J. Verweij The Netherlands A. Glaus Switzerland . Metzger Switzerland P.A. Voute The Netherlands D.M. Green USA ZOz . Mciss et France H.P. Wagner Switzerland P. Greenwald USA J.-L. Misset France R.B. Womer USA B. Gusterson UK NEWS COMMITTEE NEWS EDITOR F. Meunier (Chair), EORTC, Brussels P. Pritchard, FECS, Brussels A. Costa, ESO, Milan C. van Kalken, NDDO, Brussels Robert Short, London M. Price, EACR, Nottingham Elsevier Science Tanwen Evans, Production Editor LIST OF CONTENTS NUMBER | Announcement International Cancer News Editorial The prognostic value of cathepsin D in breast cancer. A long road to the clinic H. Rochefort Points of View The breast screening controversy M. Baum What do we know on variables influencing clinical decision-making in elderly cancer patients? 12 S. Monfardim Special Paper Cathepsin D and breast cancer 15 B.R. Westley and F.E.B. May Reviews Palliative endoscopic therapy of rectal carcinoma 25 M. Dohmoto, M. Hiinerbein and P.M. Schlag Role of oxygen free radicals in cancer development 30 D. Dreher and A.F . Funod Meeting Highlight On the threshold of success? Report on ECCO8, 29 October-2 November 1995, Paris, France 39 D.C. Purves and I.R. Hart Clinical Oncology Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? 4] F.. Perrone, C. Carlomagno, R. Lauria, M. De Laurentus, A. Morabuto, L. Panico, G. Pettnato, G. Petrella, C. Gallo, A.R. Bianco and S. De Placido A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines 47 G. Fountzilas, A. Athanassiades, T. Giannakakis, D. Bafaloukos, K. Karakousis, N. Dombros, P. Kosmadis and D. Skarlos ill List of Contents A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus 52 thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy F. Sanchaindz A . Milla An economic model to assess the savings from a clinical application of haematopoietic growth factors 57 C.A. Uyl-de Groot, E. Vellenga and F .F .H. Rutten The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer 63 A. Webb, P. Scott-Mackie, D. Cunningham, A. Norman,J .A ndreyev, M. O’Brien and7 .B ensted A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small 69 cell lung cancer C. Cotto,7 .B erille, PF. Souquet, R. Riou, B. Croisile, F. Turyman, B. Giroux,7 .B rune and V. Trillet-Lenoir The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical 72 trial 30853 F.C. da Silva, S.D. Fossa, N.K. Aaronson, S. Serbouti, L.D ems,J .C asselman, P. Whelan, 4. Hetherington, C. Fava, B. Richards, M.R.G. Robinson and the members oft he EORTC Genitourinary Tract Cancer Cooperative Group Helping cancer patients disclose their concerns 78 P. Maguire, A. Faulkner, K. Booth, C. Eliott and V. Hilher An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis 82 induced by moderate dose cisplatin-containing regimens A. Martom, B. Angelelli, M. Guaraldi, E. Strocch and F. Pannun MDRI gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of 86 bone and soft tissue sarcomas U. Stein, R.H. Shoemaaknde Pr.M . Schlag Paediatric Oncology Radiolabelled mIBG in the treatment of neuroblastoma 93 M.N. Gaze and T.E. Wheldon Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation 97 4. Pthkala, U.M. Saarinen, U. Lundstrom, K. Virtanen, K. Virkola, M.A. Sumes and E. Pesonen Cancer Epidemiology and Prevention Quality of prostate cancer data in the Cancer Registry of Norway 104 S. Harvet, S. Treth and F. Langmark Cancer of the prostate in Norway 1957-1991—a descriptive study 11] S. Harvet, S. Treth and F. Langmark Does age at the last birth affect breast cancer risk? 118 C.-C. Hsieh, H.-W. Chan, M. Lambe, A. Ekbom, H.-O. Adam and D. Trichopoulos iv List of Contents Experimental Oncology Ectopic vasopressin expression in MMTV-v-Ha-ras transgenic mice delays the onset of mammary 122 tumorigenesis K.-F .C hoot, D.A. Carter andD .M urphy Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded 128 human breast tumour tissue L. O’Dniscoll, S. Kennedy, E. McDermott, P. Kelehan and M. Clynes Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with 134 ERBB2 gene amplification A.M. Wam, FJ. Isola and P.L. Harkonen Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early 14] lymphatic spread of tumour cells B. Passlick, K. Pantel, B. Kubuschok, M. Angstwurm, A. Neher, O. Thetter, L. Schwetberer and F.R. Izbickt Inhibitions of protein kinase C and proto-oncogene expressions in NIH 3T3 cells by apigenin 146 Ying-Tang Huang, Min-Liang Kuo, Jer-Yuh Liu, Su-Yu Huang andJ en-Kun Lin The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness 152 of tumour cells 4. Timar,F .T ovar, G. Pogany, A. Ladanyi, S. Paku, E. Ras,7 .B ocsi, A.f eney and K. Lapis §R&—the establishment and characterisation of a new ovarian carcinoma cell line and xenograft model 160 X. Han, A.J. Papadopoulos, T.A. Jones, D. Sheer and K.S. Raju Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen 168 X. Xu, N. Azumi, H.G. Skelton, V.7. Hearing and D.M. Gersten Letters Adjuvant tamoxifen: 5 year control of dormant disease? 174 O. Merimsky, M. Inbar, F. Kouner and S. Chaitchik High frequency of urothelial cancers in patients with kidney transplantations for end-stage analgesic 175 nephropathy C. Bokemeyer, W.F. Thon, T. Brunkhorst, M.A. Kuczyk, R. Pichlmayr and V. Kliem Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study 176 G. Gardin, C. Barone, O. Nascimben, G. Ianmello, F . Sturba, A. Contu, P. Pronzato and R. Rosso MSH2 sequence variations and inherited colorectal cancer susceptibility 178 NF. Frogg¥a.At. tJo,yce , D.G.R. Evans, P.W. Lunt, D.F. Koch, B.J. Ponder and E.R. Maher Chemotherapy with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent 178 after platinum-based treatment G. Zanetta, S. LoM onico, A. Gabriele, D. Miceli and C. Mangiom Upper age limit for cervical cancer screening 180 S. Cecchim, A. Iossa and S. Ciatto List of Contents Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma 180 U. Reinhold, Th. Bruske and H.W. Kreysel Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC 18] Clinical Screening Group V. Urosevic, Ph. Chollet, A. Adenis,7 . Chauvergne, P. Fargeot, H. Roche, P. Kerbrat, M.A. Lentz, P. Fumoleau and B. Chevallier Octreotide treatment of chemotherapy-induced diarrhoea 182 P. Ginopoulos, Th. Papagiannis, Ch. Safnidi, F. Karvelas, K. Spyropoulos, Th. Papadas and Ch. Gogos 185 Corrections Calendar of Forthcoming Meetings Information for Authors NUMBER 2 195 International Cancer News Editorial 201 Radon and childhood cancers L. Parker and A.W. Craft Point of View High-dose chemotherapy for breast cancer 205 R.C.F. Leonard Special Paper Current and future trends in the multidisciplinary approach for high-risk breast cancer. The 209 experience of the Milan Cancer Institute G. Bonadonna Clinical Oncology Expression of p53 protein as a prognostic factor in patients with gastric cancer 215 M. Victorzon, S. Nordling, C. Haglund, 7. Lundin and P.¥. Roberts Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma 221 M. Pinsi, C. Fabns, G. Soardo, P. Tomutto, D. Vitulh and E. Bartoh vi List of Contents Evaluation of antitumour effects of docetaxel (Taxotere®) on human gastric cancers in vitro and in vivo M. Tanaka, T. Obata and T. Sasaki Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients F. Revillion, M. Hebbar, J. Bonneterre and J.P. Peyrat Postoperative adjuvant randomised trial comparing chemo-endocrine therapy, chemotherapy and 235 immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemo-endocrine Therapy for Breast Cancer (ACETBC) of Japan T. Monmoto, M. Ogawa, K. Onta, K. Sugimachi, T. Toge, K. Dohi, Y. Nomura, Y. Monden and N. Ogawa Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II 243 study U. Gatzemeter, F.A. Shepherd, T. Le Chevaler, P. Weynants, B. Cottier, H.F.M. Groen, R. Rosso, K. Mattson, H. Cortes-Funes, M. Tonato, R.L. Burkes, M. Gottfried and M. Voi Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and 249 neck cancer IN. Olver, P.G. Hughes, 7.G. Smith, K. Narayan and 3.F. Bishop Well-differentiated papillary mesothelioma of the peritoneum: a separate entity 255 K. Hoekman, G. Tognon, E.K.7. Risse, C.A. Bloemsma and 7.B. Vermorken Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response 259 and clinical outcome G. Scambia, P. Benedetti Pamici, E. Fou, G. Ferrandina, F.P.G. Leone, M. Marciano and S. Mancuso Identification of lymph node metastases by use of polymerase chain reaction (PCR) in melanoma 264 patients M. Schwiirzer-Voit, T.M. Proebstle and W. Sterry The importance of a multidisciplinary group in the treatment of soft tissue sarcomas 269 T. Wiklund, R. Huuhtanen, C. Blomquist, E. Tukiainen, M. Virolainen, P. Virkkunen, S. Asko-Seljavaara, 7.M. Bjérkenheim and I. Elomaa Spiritual healing among Norwegian hospitalised cancer patients and patients’ religious needs and 274 preferences of pastoral services T. Risberg, E. Wist, S. Kaasa, E. Lund and J. Norum Paediatric Oncology Radon in Devon and Cornwall and paediatric malignancies 282 R. Thorne, N.K. Foreman and M.G. Mott Small influence of parental educational level on the survival of children with leukaemia in The 286 Netherlands between 1973 and 1979 4.W.W. Coebergh, A. van der Does-van den Berg, W.C.7. Hop, F. van Weerden, 7.A. Rammeloo, H.A. van Steensel, E.R. van Wering and W.A. Kamps Vil List of Contents Information about diagnosis and prognosis related to anxiety and depression in children with cancer 290 aged 8-16 years B.F. Last and A.M.H. van Veldhuizen Cancer Epidemiology and Prevention Survival for colon and rectal cancer in a population-based cancer registry 295 L. Roncucct, R. Fante, L. Losi, C. Di Gregorio, A. Micheli, P. Benatti, N. Madenis, D. Ganazzi, M.T. Cassinadn, P. Launola and M. Ponz de Leon The role of reproductive and menstrual factors in cancer of the breast before and after menopause 303 R. Talamim, S. Franceschi, C. La Vecchia, E. Negn, L. Borsa, M. Montella, F. Falcimi, E. Conti and C. Rosst Experimental Oncology Lack of effect of corticosteroids and tamoxifen on suramin protein binding and in vitro activity 31] D.L. Driscoll, R. W. Steinkampf, L.J. Paradiso, C.D. Kowal and W.D. Klohs Red blood cell polyamines, anaemia and tumour growth in the rat 316 V. Quemener, F.Y. Bansard, M. Delamaire, S. Roth, R. Havous, D. Desury and 7.-Ph. Moulinoux Reversion of UVC-induced tumorigenic human hybrid cells to the non-tumorigenic phenotype 322 C. Sun, R. F. Antomionio and 7. L. Redpath Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma 328 cells in vitro R. Riesenberg, C. Fuchs and M. Knegmair Frequent 7P53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small 335 cell lung Cancer R. Shipman, P. Schraml, M. Colombi, G. Raefle, P. Dalquen and C. Ludwig Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell 342 growth in vitro M.J. Seckl and E. Rozengurt Newly established MST-1 tumour cell line and tumour-infiltrating lymphocyte culture from a 346 patient with soft tissue melanoma (clear cell sarcoma) and their potential applications to patient immunotherapy S.-K. Liao, Y.-P. Perng, L.-A. Lee, K.S.S. Chang, G.-M. Lat, E. Wong and Y.-S. Ho Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma 357 M. Karlsson, B. Boeryd, . Carstensen, B. Franlund, B. Gustafsson, B. Kagedal, X.-F. Sun and S. Wingren Short Communications Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by 363 immunocytochemical staining S. Thorban, 7.D. Roder, K. Pantel and .R. Siewert Vili List of Contents Retinoic acid concentrations in patients with squamous cell carcinoma of the head and neck 366 P. Wahlberg and G. Fex Letters 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? 368 T. Lieutaud, E. Brain, D. Golgran-Toledano, F. Vincent, E. Cuitkovic, B. Leclercq and B. Escudier Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in 369 a breast cancer patient with osteogenesis imperfecta P. Beuzeboc, F.-Y. Pierga, D. Stoppa-Lyonnet, M.C. Etienne, G. Milano and P. Pouillart Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 370 63 cases L. Cany, C. Toulouse, A. Ravaud, M. Durand and L. Maunac Studies of HLA-A and DR locus deletions in human liver cancer cell lines by PCR 371 Qing Li, S. H. Chan and E. C. Ren Adenocarcinoma of the eccrine sweat gland: response to both combination chemotherapy and local 372 field irradiation W.C. Mertens, D.T. Shum and 7.A. Gilchrist Chemotherapy-induced onycholysis 374 A. Maknis, P. Mortimer and T.7. Powles Prevention of second primary tumours with a second generation retinoid in squamous cell 375 carcinoma of oral cavity and oropharynx: long term follow-up M. Bolla, A. Laplanche, R. Lefur, J. Ton Van, C. Domenge, J.-L. Lefebvre and B. Luboinski for the French Study Group on Head and Neck Tumour (GETTEC) France “Tt feels better’>—measuring clinical benefit 376 D.D. Von Hoff Calendar of 379 Forthcoming Meetings Information for Authors NUMBER 3 International 387 Cancer News Editorials Cancer genetics clinics 39] D.G.R. Evans, F. Cuzick and A. Howell ix List of Contents New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity 393 M. Castighone-Gertsch Point of View Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced 396 growth factor and immune-suppression mediated tumour progression R.T.D. Olver, ¥. Tobias and C. Gallagher Special Paper Cancer genetics clinics: target population and consultees’ expectations 398 C. Fulian-Reymer, F. Eisinger, F. Chabal, Y. Aurran, C. Nogueés, P. Vennin, Y.-7. Bignon, M. Machelard-Roumagnac, C. Maugard-Louboutin, D. Senin, S. Versini, M. Mercun and H. Sobol Clinical Oncology A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole 404 (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer W. Fonat, A. Howell, C. Blomquist, W. Eermann, G. Winblad, C. Tyrrell, L. Maunac, H. Roche, S. Lundgren, R. Hellmund and M. Azab on behalf of the ARIMIDEX Study Group Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal 413 growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer R.A. McClelland, 7.M.W. Gee, A.B. Francis, J.F.R. Robertson, R.W. Blamey, A.E. Wakeling and R.I. Nicholson Prognosis of patients with breast cancers up to | cm in diameter 417 I.S. Fentiman, D. Hyland, M.A. Chaudary and W.M. Gregory Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in 421 untreated advanced epithelial ovarian cancer: a Hellenic Co-operative Oncology Group study D.V. Skarlos, G. Aravantinos, P. Kosmidis, N. Pavlidis, K. Gennatas, M. Beer, N. Mylonakis, P. Makrantonakis, G. Klouvas, S. Karpathios, H. Linardou, C. Konstantaras and G. Fountzilas Combined intensive chemoradiotherapy for organ preservation in patients with resectable and 429 non-resectable oesophageal cancer E. Roca, E. Pennella, M. Sardi, S. Carraro, M. Barugel, C. Milano, A. Fiorm, R. Gigho, G. Gonzalez, R. Kneitschel, E. Aman, A. Jarentchuk, C. Blajman, 7. Nadal, M.T. Santarelli and A. Navigante Prognostic value of resection-line involvement in patients undergoing curative resections for gastric 433 cancer I. Songun, 7.7. Bonenkamp, 7. Hermans, }.H.7.M. van Knieken, C.J.H. van de Velde and Co-operating Investigators oft he Dutch Gastric Cancer Trial Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, 438 with and without maintenance chemotherapy in patients with small cell carcinoma of the lung 3.M. Beith, S.J. Clarke, R.L. Woods, D.R. Bell and 7.A. Levi X